←
CardiovascularCorner14,722 posts
CardiovascularCorner avatar

CardiovascularCorner

@TrackYourHeart

Making cardiovascular medicine as simple as possible, but not simpler. ECG| ECHO| CMR| CXR |Interventional |MedEd Tweets are only for educational purposes.

◷ Joined August 2024▧ 8,186 Photos and videos
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·7h

CARDIAC SURGERY MASTERCLASS: CARDIOPULMONARY BYPASS (CPB) How does a cardiopulmonary bypass circuit keep a patient alive while the heart and lungs are temporarily bypassed during cardiac surgery? This schematic illustrates a typical CPB circuit using a membrane oxygenator. Follow the blood flow: 1. VENOUS DRAINAGE Deoxygenated blood flows from the right atrium through the venous cannula into the venous reservoir. 2. BLOOD PUMP A roller or centrifugal pump propels blood through the circuit, generating systemic blood flow. 3. MEMBRANE OXYGENATOR The oxygenator adds oxygen and removes carbon dioxide, temporarily performing the gas-exchange function of the lungs. 4. HEAT EXCHANGER Blood temperature is regulated to support the required temperature during surgery. 5. ARTERIAL FILTER The filter and bubble trap help remove particulate matter and air before blood returns to the patient. 6. ARTERIAL RETURN Oxygenated blood is delivered through the arterial cannula into the ascending aorta, supplying the systemic circulation. ADDITIONAL CIRCUIT COMPONENTS 🟢 Cardioplegia system: delivers cardioplegic solution to produce myocardial arrest and protect the heart. 🟡 Cardi otomy reservoir: collects blood aspirated from the operative field. 🔵 LV vent: helps decompress the left ventricle. 🔴 Suction lines: return aspirated blood to the reservoir. ⚫ Pressure and temperature sensors: monitor circuit conditions. 🟣Air-bubble detectors: help identify air before it reaches the patient. ⚪ One-way valves and clamps: help prevent reverse flow and allow circuit isolation. CLINICAL PEARL The CPB circuit temporarily takes over two essential functions: ✅The heart's pumping function and the lungs' gas-exchange function. Understanding the direction of blood flow through each component is fundamental to cardiac anaesthesia, perfusion and cardiothoracic surgery. @TrackYourHeart

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·3h

Treatment of Essential Hypertension (Adults) Step 1 ◻️ Age <55 years: Start an ACE inhibitor (ACEi) or ARB (ARB if ACEi is not tolerated). ◻️ Age ≥55 years or Black African/Black Caribbean ethnicity: Start a calcium channel blocker (CCB). Step 2 ◼️ACEi/ARB + CCB ◼️ If a CCB is not tolerated, use a thiazide-like diuretic instead. Step 3 ◻️ ACEi/ARB + CCB + thiazide-like diuretic Step 4 (Resistant Hypertension) ◻️ If serum potassium is ≤4.5 mmol/L: Add low-dose spironolactone. ◻️ If serum potassium is >4.5 mmol/L: Consider an alpha-blocker or beta-blocker, or seek specialist advice. Key point: Use either an ACE inhibitor or an ARB, never both together. Reference: NICE Guideline NG136: Hypertension in adults: diagnosis and management (updated February 2026).

Post attachment
الحساب الثالث avatar
⟳ CardiovascularCorner retweeted
الحساب الثالث@Qataaada·Nov 17

موقع رهيب لتعلم Heart and lung auscultatilon تكرر سماع ثم يختبرك بالأصوات وينبهك كل murmur مرتبط بأي حالة تقدر تسمع بالاثنين diaphragm and Bell وكل sound عند كل area كيف يظهر في حتى ECG بس ما جربته medaralearning.com

Post attachmentPost attachmentPost attachmentPost attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

11/11 Follow-up, surveillance and treatment duration Treatment does not end when anticoagulation is started. Follow-up imaging helps determine whether the thrombus has resolved and whether anticoagulation can be stopped. A practical approach described in the review: 1️⃣ Repeat imaging at around 3 months. 2️⃣ Use the same or a more sensitive modality; consider CMR if TTE is inconclusive. 3️⃣ If thrombus persists, reassess anticoagulation, adherence and INR control where relevant, then repeat imaging after further treatment. 4️⃣ If anticoagulation is stopped, consider repeat TTE around 3 months later to assess recurrence. For selected high-risk patients without thrombus on the initial scan, early repeat contrast TTE may be considered. The central message: individualize treatment according to thrombus resolution, LV recovery, embolic risk and bleeding risk. Source: Camaj A, et al. Left Ventricular Thrombus Following Acute Myocardial Infarction: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:971–986.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

10/11 Antithrombotic strategy after MI and PCI Managing LV thrombus after PCI presents a difficult balance: anticoagulation is needed for the thrombus, while antiplatelet therapy may be needed to protect the coronary stent. Combining oral anticoagulation with dual antiplatelet therapy increases bleeding risk. Practical principles: ⭕ Keep triple therapy as short as clinically appropriate. ⭕ In suitable patients, transition to oral anticoagulation plus a single P2Y12 inhibitor, usually clopidogrel. ⭕ Individualize treatment according to stent-thrombosis risk, bleeding risk and PCI complexity. ⭕ Reassess the need for antiplatelet therapy when anticoagulation is stopped. The 2025 position-paper and guideline points shown here should be interpreted in their stated context: some recommendations are extrapolated from broader ACS/OAC evidence, because LV-thrombus-specific randomized data remain limited.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

9/11 Anticoagulation treatment Confirmed LV thrombus after MI generally warrants oral anticoagulation to reduce systemic embolic risk. Warfarin (VKA) has historically been the most established treatment. The 2022 AHA Scientific Statement describes approximately 3 months of oral anticoagulation for post-MI LV thrombus, commonly targeting an INR of 2.0-3.0. DOACs, including apixaban and rivaroxaban, are reasonable alternatives in selected patients, but the evidence base is less established; superiority over warfarin should not be assumed. Heparin may be used in selected situations, but routine bridging is not required for every patient. Treatment duration and agent choice should account for thrombus resolution, LV function, bleeding risk, renal function and patient-specific factors.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

8/11 Thromboembolic risk and clinical outcomes The major complication of LV thrombus is systemic embolization. Potential consequences include: 🔻 Ischaemic stroke. 🔻 Acute limb ischaemia. 🔻 Renal, splenic or mesenteric infarction. The review describes substantial embolic event rates in observational cohorts. Risk is influenced by thrombus mobility and protrusion, LV dysfunction and the adequacy of anticoagulation. One important observation: in a study cited by the review, patients with warfarin time in therapeutic range below 50% had more systemic embolism than those with TTR of at least 50% (19% vs 3%). Persistent thrombus is also associated with worse outcomes, although it may partly reflect persistent LV dysfunction rather than directly cause mortality.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

7/11 Other imaging and embolic risk What if TTE and CMR are not available or more information is needed? Cardiac CT may identify LV thrombus incidentally or during coronary CT imaging, but it is not yet a validated standard diagnostic modality for this indication. Molecular imaging, including 18F-GP1 PET, has shown potential for detecting platelet activity within thrombus, but remains investigational. When assessing embolic risk, document: ⚪ Mobility. ⚪ Protrusion into the LV cavity. ⚪ Thrombus size and morphology. ⚪ Timing relative to MI. Mobile and protruding thrombi are generally more concerning than stable, mural thrombi.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

6/11 Diagnosis: Transthoracic echocardiography Transthoracic echocardiography (TTE) is usually the initial imaging test for suspected LV thrombus after MI. Typical findings include an echo-dense mass distinct from the endocardium, often at the apex and adjacent to an akinetic or hypokinetic segment. The limitation is sensitivity: 🟦 TTE without contrast: 21-35% sensitivity; 95-98% specificity. ⬜ Contrast-enhanced TTE: approximately 64% sensitivity; 99% specificity. An ultrasound-enhancing agent improves endocardial border definition and thrombus detection. If suspicion remains high despite a nondiagnostic TTE, consider CMR. TEE has limited additional value for assessing the LV apex.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

5/11 · Diagnosis: Cardiac MRI Cardiac magnetic resonance (CMR) is the most sensitive imaging modality for LV thrombus. Late gadolinium enhancement (LGE) is particularly useful: because thrombus is avascular, it does not take up gadolinium and appears as a dark filling defect against the enhanced myocardium. Reported diagnostic performance in the review: 🟢 Sensitivity: 82-88%. 🟡 Specificity: approximately 100%. CMR can also assess infarct size, scar burden, LV function and apical morphology. Consider it when TTE is negative or inconclusive despite strong clinical suspicion, or when more detailed characterization is needed.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

4/11 Pathophysiology, anatomy and natural history LV thrombus formation is a dynamic process. After MI, endothelial injury, impaired ventricular contraction and local blood stasis promote fibrin, platelet and red-cell accumulation. The LV apex is particularly vulnerable because it is often the region of greatest stasis. Thrombus morphology evolves: 🟥 Acute: often protruding and/or mobile. ⬜ Chronic: more likely to become mural, laminated and adherent. Mobility and protrusion are important imaging features when assessing embolic risk. More than half of thrombi may resolve by 6 months, although persistence can occur.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

3/11 · Epidemiology and Virchow’s triad Why does an LV thrombus form after MI? The mechanism is explained by Virchow’s triad: 1️⃣ Endothelial injury: infarction damages the endocardial surface and triggers inflammation. 2️⃣ Blood stasis: LV dysfunction and apical akinesis/dyskinesis reduce blood flow. 3️⃣ Hypercoagulability: the post-infarction inflammatory and prothrombotic state promotes clot formation. These mechanisms also provide potential therapeutic targets: reperfusion, optimization of LV function and anticoagulation when thrombus is present.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

2/11 Overview and clinical significance LV thrombus is a potentially serious complication of MI. It most often develops after a large anterior MI, particularly when there is reduced LV function and apical akinesis or dyskinesis. Key points: ◼️ The LV apex is the most common location. ◼️ Many thrombi develop within the first 2 weeks. ◻️ Systemic embolism, especially ischaemic stroke, is the major concern. ◻️ CMR is more sensitive than conventional TTE for detecting LV thrombus. Early recognition matters.

Post attachment
CardiovascularCorner avatar
CardiovascularCorner@TrackYourHeart·10h

Left ventricular thrombus remains an important complication of acute myocardial infarction, particularly after large anterior infarctions. Why does it develop? How do we detect it? Who needs anticoagulation, and for how long? This 🧵 explores the epidemiology, pathophysiology, diagnosis, embolic risk and management of post-MI LV thrombus.

Post attachment